+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, and Geography

  • ID: 5028563
  • Report
  • April 2020
  • Region: Europe
  • 105 pages
  • The Insight Partners
UP TO OFF
until Jun 30th 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Altimmune
  • Bavarian Nordic
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Pluristem Therapeutics
  • MORE
Europe, the Biodefense Market, is anticipated to reach US$ 2,516.91 Mn in 2027 from US$ 1,286.58 Mn in 2019. The market is projected to grow with a CAGR of 8.8% from 2020-2027.

The Biodefense Market is growing primarily due to the presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Restraining factors, such as fluctuations in funding due to changing EU likely to damage the growth of the market in the coming years. Additionally, increased adoption of technologies and predictive analytics to reshape biodefense market are likely to increase the growth of the biopharmaceuticals contract manufacturing in the forecast period.

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

The government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks every year. For instance, in 2018, the UK government released the Biological Security Strategy, Strategic Defense and Security Review, Global Health Security and UK Antimicrobial Resistance Strategy and the National Counterterrorism Strategy, counter terrorism strategy CONTEST, the National Counter-Proliferation Strategy to 2020, the UK Influenza Preparedness Strategy, the Strategy for UK Life Sciences, the Vision and high level Strategy for UK Animal and Plant Health Research to 2020 and Beyond, and the Strategy for Agricultural Technologies and the Department for International Development's (DFID's) 2016 Research Review, all of these include biosecurity and biodefense.

In 2013, the Federal Foreign Office launched the German Biosecurity Programmed in order to implement long term biosecurity projects in various countries under the auspices of the G7 Global Partnership against the Spread of Weapons and Materials of Mass Destruction. With a budget of over 25 million euros for the 2013-16 period and a further 19.5 million euros for 2017-19, we are helping partner countries to minimize biosecurity threats. This helps to immediately recognize outbreaks of dangerous and highly contagious diseases, reduce infection and swiftly identify and eliminate the causes. As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. The initiatives of governments worldwide open a window of opportunities for the firms involved in the biodefense sector. Thus, owing to the factors mentioned above are likely to boost the growth of the Biodefense Market in Europe during the forecast period.

In 2019, the anthrax segment accounted for the largest market share in the Biodefense Market in Europe. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioWeapons Prevention Project (BWPP), British American Security Information Council (BASIC), and the German Biosecurity Programme.

Some of the significant secondary sources for cold plasma equipment included in the report are the World Health Organization (WHO) and the Food and Drug Administration (FDA).

Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biodefense market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Altimmune
  • Bavarian Nordic
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Pluristem Therapeutics
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Europe Biodefense market - By Product
1.3.2 Europe Biodefense market - By Country

2. Europe Biodefense Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Biodefense market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Biodefense market - Europe PEST Analysis
4.3 Expert Opinion

5. Europe Biodefense Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Presence of Favourable Government Initiatives
5.1.2 Increase in the Number of Naturally Occurring Outbreaks
5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM
5.2 Key Market Restraints
5.2.1 Fluctuations in funding due to the changing EU & government policies
5.3 Key Market Opportunities
5.3.1 Increased Adoption of Technologies
5.4 Future Trends
5.4.1 Predictive Analytics to Reshape Biodefense Market
5.5 Impact Analysis

6. Biodefense Market - Europe Analysis
6.1 Europe Biodefense Market Revenue Forecasts and Analysis

7. Europe Biodefense market Analysis And Forecasts To 2027 - By Product
7.1 Overview
7.2 Europe Biodefense market, By Product 2019 & 2027 (%)
7.2.1 Europe Biodefense market Revenue and Forecasts to 2027, By Product (US$ Mn)
7.3 Anthrax
7.3.1 Overview
7.3.2 Europe Anthrax Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Small pox
7.4.1 Overview
7.4.2 Europe Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Botulism
7.5.1 Overview
7.5.2 Europe Botulism Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Radiation/Nuclear
7.6.1 Overview
7.6.2 Europe Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. Biodefense market Revenue and Forecasts To 2027 - Geographical Analysis
8.1 Europe Biodefense market Revenue and Forecasts To 2027
8.1.1 Overview
8.1.2 Europe: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.3 Europe: Biodefense Market, by Product, 2018-2027 (USD Million)
8.1.4 Europe: Biodefense Market, by Country, 2018 & 2027 (%)
8.1.5 Germany: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.5.1 Germany: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.5.2 Germany: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.6 UK: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.6.1 UK: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.6.2 UK: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.7 France: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.7.1 France: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.7.2 France: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.8 Spain: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.8.1 Spain: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.8.2 Spain: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.9 Italy: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.9.1 Italy: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.9.2 Italy: Biodefense Market, by Product Type, 2018-2027 (USD Million)

9. Impact 0f Covid-19 Pandemic On Europe Biodefense Market
9.1 Europe: Impact assessment of COVID-19 Pandemic

10. Europe Biodefense market Industry Landscape
10.1 Overview
10.2 Growth Strategies in The Biodefense Market, 2016-2020
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview

11. Company Profiles
11.1 Bavarian Nordic
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Alnylam Pharmaceuticals, Inc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 SIGA Technologies
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Emergent BioSolutions Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Cleveland Bio Labs
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • Pluristem Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll